NA
Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Alzheimers Disease Therapeutics Market size was estimated at over USD 6.9 billion in 2024 and is poised to reach USD 56.7 billion by the end of 2037, expanding at a CAGR of 19.2% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of alzheimers disease therapeutics is evaluated at USD 8.2 billion.
The proven efficacy of therapeutics as an effective treatment solution is driving growth in the Alzheimers disease therapeutics market. The rising prevalence of Alzheimers disease and advancements in diagnostic technologies are encouraging global leaders to launch more of such effective therapeutics. According to a WHO report published in March 2025, 57 million people were residing with dementia in a year, with more than 60% of people living in developing countries, and approximately 10 million new cases were reported annually. It further stated that Alzheimers disease accounted for 60% to 70% of dementia cases, which is the seventh leading cause of death worldwide. These rising instances further inflate the demand for such therapeutics.
In addition, the rising awareness about the treatment procedures across the world led to an upsurge in demand for innovative therapies aimed at slowing the disease progression, further improving the quality of life. For instance, in March 2025, Alpha Cognition Inc. launched ZUNVEYL (Benzgalantamin), that is the first oral FDA approved treatment which is meant to be indicated for mild to moderate Alzheimers disease. These substantial launch activities by the industry are further inspiring pharmaceutical leaders to introduce more effective solutions, such as Alzheimers disease therapeutics, for solidifying their positions in the global landscape of this sector.
Alzheimers Disease Therapeutics Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing investments in the sector: The proven effectiveness of these drugs encourages the biotechnology and pharmaceutical firms to invest significantly in the sector, allowing market progression. Due to the increased occurrence of neurodegenerative disorders, companies are actively pursuing development activities. For instance, in December 2020, Novo Nordisk announced that it entered phase 3 development in AD with 14 mg oral semaglutide, which is a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. It further reported to initiate the program with 3,700 individuals with the disease, thereby uplifting market demand.
- Increasing research activities: With ongoing research activities in the healthcare sector, the frequency of advancements in the Alzheimers disease therapeutics market increases. The research activities aim to mitigate the route of administration issues and develop more accurate detection strategies. As of April 2025, NIH reports that researchers analyzed cerebrospinal fluid samples from 3,400 individuals across the U.S., Sweden, and Finland and found that the YWHAG: NPTX2 protein ratio more accurately reflects cognitive decline in AD patients than existing biomarkers. This ratio is a promising tool to predict and track AD progression, thus driving demand for innovative solutions.
Challenges
- Limitations in affordability and availability: One of the major restraints for the market is the limitation in affordability and availability. These expenses can create an economic barrier among the people who belong to price-sensitive regions. These costs are further exacerbated by the high costs associated with PET scans, biomarker testing, and biologics, further limiting market expansion of this sector. In addition, the inadequate healthcare infrastructure and lack of skilled professionals hinder the effective management of the disease, restricting product exposure across the healthcare industry.
- Clinical trial failures: Despite having limited adverse reaction cases, growth in the market can be hindered due to the failure rate of clinical trials, particularly for disease-modifying therapies. Besides the substantial investments by the key players, many therapeutics fail to demonstrate efficacy in slowing or reversing cognitive decline, limiting market penetration. This may further create a hurdle for this sector to capture the optimum consumer base in the therapeutic industry. Hence, the higher failure rate of clinical trials limits the market expansion.
Alzheimers Disease Therapeutics Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
19.2% |
|
Base Year Market Size (2024) |
USD 6.9 billion |
|
Forecast Year Market Size (2037) |
USD 56.7 billion |
|
Regional Scope |
|
Alzheimers Disease Therapeutics Segmentation
Route of Administration (Oral, Injectable)
Based on route of administration, the oral segment is expected to garner the highest share of 63.6% in the alzheimers disease therapeutics market by the end of 2037. The ease of administration and the painless way of drug delivery are anticipated to augment the segment growth. Additionally, the patient can consume it regardless of the place, which is the key factor driving the segment's growth. In May 2023, the U.S FDA announced that it approved Rexulti (brexpiprazole) oral tablets that are meant to be indicated for treating agitation symptoms that are associated with dementia due to AD. Thus, this denotes a positive outlook for the segment’s growth, driving significant outcomes during the forecast timeline.
Drug Class (Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drug, Pipeline Drugs)
Based on the drug class, the cholinesterase inhibitors segment is projected to grow at a considerable rate in the alzheimers disease therapeutics market during the forecast period. The growth is attributable to the drug’s enhanced efficacy in relieving symptoms and improving cognitive function. For instance, in April 2024, Essential Pharma finalized the acquisition of Reminyl (galantamine hydrobromide) cholinesterase inhibitor from Janssen Pharmaceutica NV, a Johnson & Johnson company, to treat dementia in AD patients. Hence, the market will witness lucrative growth activities with such improved acquisitions further inspiring companies to develop more effective treatment alternatives.
Our in-depth analysis of the global alzheimers disease therapeutics market includes the following segments:
|
Route of Administration |
|
|
Drug Class |
|
|
Disease Stage |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAlzheimers Disease Therapeutics Industry - Regional Synopsis
North America Market Analysis
The North America alzheimers disease therapeutics market is poised to capture the largest share of 47.9% during the forecast period. The increased healthcare expenditure in terms of research and development by the global leaders and the rising government initiatives are the key drivers for growth in the region. In December 2021, Biogen Inc. and Eisai Co., Ltd. together announced that lecanemab, an anti-amyloid beta (Aβ) protofibril antibody for the treatment of early AD, was granted fast track designation by the U.S. FDA to address the unmet medical needs. This highlights the growing need for advanced drugs such as Alzheimers disease therapeutics in this region.
The U.S. has become the hub for global leaders in the market due to its wide consumer base and excellent manufacturing facilities. The country fosters a favorable environment for organizations to expand their business with a huge population adapting to the developing therapeutics along with technologies. For instance, in March 2025, Eli Lilly and Company notified the expansion of its LillyDirect digital healthcare platform to improve AD care in the U.S., to connect individuals with in-person and telehealth providers to enhance diagnostic capacity by reducing delays. Thus, it inspires other domestic participants to establish their footprint in this country by promoting the need for early detection.
Canada is steadily consolidating its position in the Alzheimers disease therapeutics market with proactive government approvals and ongoing clinical trials. The concerning growth in Alzheimers disease cases is pushing the international players to promote available treatment options and develop new therapeutics. In January 2025, Toronto Memory Program became the first clinic in Canada to offer C2N Diagnostics PrecivityAD2 blood test. The test allows healthcare professionals to diagnose AD by detecting amyloid pathology using a simple, non-invasive process. This is further inflating demand in this sector due to the high requirement for early detection & Alzheimers disease therapeutics in the country.
APAC Market Statistics
Asia Pacific is expected to demonstrate the fastest growth in the alzheimers disease therapeutics market, with its strong capacity in biotechnology and ongoing research & development in AD therapeutics. The region hosts growth factors driven by the developmental trajectory of countries such as Australia, Japan, India, and China. The region’s aging population is experiencing a heavy incidence of the disease, which is increasing the awareness among the domestic players to develop new therapeutic drugs and elevate their production. Thus, the growth in this region is further carried forward with the high demand for cost-effective treatment procedures and the continuous efforts of organizations that are researching to bring innovations in this field.
India is propagating the regional market with its strong pharmaceutical development and government support. The country leverages a huge patient pool with rising instances of dementia, which necessitates the need for effective therapeutics. For instance, in October 2025, as published by the Government of India, the Ministry of Science & Technology reported that scientists from Agharkar Research Institute, Pune, developed novel, non-toxic molecules for treating AD using synthetic, computational, and in vitro techniques that demonstrated low toxicity, improving the efficacy. Thus, such innovations with enhanced patient safety measures are expected to augment the market expansion in the country.
China is one of the major hubs for the market, which is emerging as a great manufacturing source. The increasing demand for new therapies and great support from the government offer a favorable business environment, encouraging international leaders. In May 2024, AriBio Co., Ltd received IND approval from China’s NMPA to begin a phase 3 clinical trial for its investigational drug AR1001 targeting Alzheimers disease. It further stated that the Polaris-AD trial will be conducted at up to 20 clinical centers across the country. Hence, these ongoing trials are readily blistering the market with positive outcomes.
Companies Dominating the Alzheimers Disease Therapeutics Landscape
- AbbVie Inc. (Allergan Plc.)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Adamas Pharmaceuticals, Inc.
- Lundbeck A/S
- Eli Lilly and Company
- Biogen Inc.
- AC Immune
- Hoffmann La Roche Ltd.
- AriBio Co., Ltd
- Daiichi Sankyo Company, Limited
- Johnson & Johnson Services, Inc.
- TauRx Pharmaceuticals Ltd.
The competitive demographic of the market is inspiring global leaders to increase their research and development investments to develop new, exclusive therapeutic formulations. In addition, the ongoing growth policies by each player are drawing the focus of other competitors to participate, encouraging a healthy competition. For instance, in January 2024, Biogen Inc. declared its plan to reprioritize its Alzheimers disease resources by discontinuing ADUHELM and focusing on advancing LEQEMBI (lecanemab-irmb). It further reported to accelerate the therapies, such as BIIB080 & BIIB113, aiming to build a new franchise. Thus, this ensures a positive outlook for the market upliftment with such effective strategies.
A few of the key players in the market include:
In the News
- In January 2025, Eisai Co., Ltd. with Biogen Inc., declared the U.S FDA clearance of Supplemental Biologics License Application (sBLA) for LEQEMBI’s IV maintenance dosing for AD treatment.
- In July 2024, Eli Lilly and Company notified that its Kisunla (donanemab-azbt) 350 mg/20 mL received approval from the U.S. FDA for the treatment of early symptomatic Alzheimers disease in adults.
Author Credits: Radhika Pawar
- Report ID: 7599
- Published Date: May 07, 2025
- Report Format: PDF, PPT
